Evaluation of the Effectiveness of the Risk Minimization Measures of Sodium Oxybate in the European Union

• Auteurs principaux: Alex Iranzo (Auteur), Pedro Serralheiro (Auteur), Jan-Christof Schuller (Auteur), Anne-Françoise Schlit (Auteur), Jürgen W. G. Bentz (Auteur)
• Format: Livre
• Publié: Adis, Springer Healthcare, 2020-09-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

Abstract Background Sodium oxybate (Xyrem®), approved by the European Medicines Agency (EMA) for narcolepsy with cataplexy, is only available through risk mitigation programs due to potential adverse effects including respiratory and central nervous system depression, neuropsychiatric events, and mi...